Ohata Keiji, Chen-Yoshikawa Toyofumi F, Takahashi Koji, Aoyama Akihiro, Motoyama Hideki, Hijiya Kyoko, Hamaji Masatsugu, Menju Toshi, Sato Toshihiko, Sonobe Makoto, Takakura Shunji, Date Hiroshi
Department of Thoracic Surgery, Kyoto University, Kyoto, Japan.
Department of Infection Control and Prevention, Kyoto University, Kyoto, Japan.
Interact Cardiovasc Thorac Surg. 2017 Nov 1;25(5):710-715. doi: 10.1093/icvts/ivx226.
Cytomegalovirus (CMV) infection remains a major cause of morbidity after lung transplantation. Some studies have reported prognostic factors for the postoperative development of CMV infection in cadaveric lung transplantation (CLT), but no research has been performed in living-donor lobar lung transplantation (LDLLT). Therefore, we analysed the possible risk factors of post-transplant CMV infection and the differences between LDLLT and CLT.
The development of CMV disease and viraemia in 110 patients undergoing lung transplantation at Kyoto University Hospital in 2008-2015 were retrospectively assessed. The prognostic factors in the development of CMV infection and the differences between LDLLT and CLT were analysed.
Among 110 patients, 58 LDLLTs and 52 CLTs were performed. The 3-year freedom rates from CMV disease and viraemia were 92.0% and 58.5%, respectively. There was no difference in the development of CMV infection between LDLLT and CLT (disease: 94.6% vs 91.0%, P = 0.58 and viraemia: 59.3% vs 57.2%, P = 0.76). In preoperative anti-CMV immunoglobulin status, R-D+ recipients (recipient: negative, donor: positive) and R-D- recipients (recipient: negative, donor: negative) tended to have higher and lower cumulative incidences, respectively, of CMV infection (disease: P = 0.34 and viraemia: P = 0.24) than that with R+ recipients (recipient: seropositive). Significantly lower cumulative incidence of CMV viraemia was observed in patients receiving 12-month prophylactic medication (70.6% vs 36.8%, P < 0.001). Twenty-eight patients (25.5%) had early cessation of anti-CMV prophylaxis due to toxicity; however, the extended prophylaxis duration did not increase the incidence of early cessation (P = 0.88). These trends were seen in both LDLLT and CLT.
We found that there was no difference in the development of CMV infection between LDLLT and CLT. Twelve-month prophylaxis protocol provides beneficial effect without increased toxicity also in LDLLT.
巨细胞病毒(CMV)感染仍是肺移植术后发病的主要原因。一些研究报道了尸体肺移植(CLT)术后CMV感染发生的预后因素,但活体供肺叶移植(LDLLT)方面尚未有相关研究。因此,我们分析了移植后CMV感染的可能危险因素以及LDLLT和CLT之间的差异。
回顾性评估2008年至2015年在京都大学医院接受肺移植的110例患者的CMV疾病和病毒血症的发生情况。分析CMV感染发生的预后因素以及LDLLT和CLT之间的差异。
110例患者中,进行了58例LDLLT和52例CLT。CMV疾病和病毒血症的3年无病生存率分别为92.0%和58.5%。LDLLT和CLT之间CMV感染的发生情况无差异(疾病:94.6%对91.0%,P = 0.58;病毒血症:59.3%对57.2%,P = 0.76)。在术前抗CMV免疫球蛋白状态方面,R-D+受者(受者:阴性,供者:阳性)和R-D-受者(受者:阴性,供者:阴性)的CMV感染累积发生率分别倾向于高于和低于R+受者(受者:血清学阳性)(疾病:P = 0.34;病毒血症:P = 0.24)。接受12个月预防性用药的患者中,CMV病毒血症的累积发生率显著较低(70.6%对36.8%,P < 0.001)。28例患者(25.5%)因毒性反应提前停止抗CMV预防;然而,延长预防时间并未增加提前停止的发生率(P = 0.88)。这些趋势在LDLLT和CLT中均可见。
我们发现LDLLT和CLT之间CMV感染的发生情况无差异。12个月的预防方案在LDLLT中也具有有益效果且不增加毒性。